Ir a inicio
Saban Sec
13
años de experiencia
4.9
Calificación

Saban Sec

  • Especialidad: Oncólogo clínico
  • 13 años de experiencia
  • Idiomas:
    Turco
  • Consultorio: Turquía, Estambul, Valued Med Hub Hospitals
  • Representante de Médicos Especialistas de la Asociación Turca de Oncología Médica desde 2022. Miembro de la Cámara Médica de Estambul y de la Asociación Turca de Oncología Médica.

    El Dr. Saban Sec es oncólogo médico con experiencia en hospitales de prestigio como el Hospital de Formación e Investigación Haseki, el Hospital Municipal Prof. Dr. Cemil Taşcıoğlu y el Hospital Bahçelievler Medikalpark. Actualmente representa a los médicos especialistas en la Asociación Turca de Oncología Médica. También es miembro de la Cámara Médica de Estambul y de la Asociación Turca de Oncología Médica.

    El Dr. Sec trata cánceres de mama, pulmón, gastrointestinales, de próstata, urogenitales, de cabeza y cuello, así como sarcomas y tumores raros. Ha publicado numerosos artículos revisados por pares sobre pronóstico, resultados de tratamiento y tasas de supervivencia en cáncer. Su investigación incluye estudios con grandes grupos de pacientes, como 138 casos de cáncer gástrico metastásico HER2 positivo. El Dr. Sec se especializa en factores pronósticos y respuestas al tratamiento en distintos tipos de cáncer, y está comprometido con mejorar la atención oncológica.

Servicios médicos

Ver más

¿Qué tal su experiencia?

1 de 3
La información sobre este doctor es completa y clara
1
2
3
4
5
Totalmente en desacuerdo
Totalmente de acuerdo

Formación académica

Experience

2012-2017 Haseki Training and Research Hospital Internal Medicine

2017 Kanuni Sultan Süleyman Training and Research Hospital Internal Medicine Specialist Dr.

2017-2021 Prof. Dr. Cemil Taşcıoğlu City Hospital Medical Oncology

2021-2022 Şanlıurfa Mehmet Akif İnan EAH Medical Oncology Specialist Dr.

2022 Bahçelievler Medikalpark Hospital

2022- Turkish Medical Oncology Association Specialist Physicians Representative

 

Professional Memberships

1) Istanbul Medical Chamber Member

2) Turkish Medical Oncology Association Member

 

Areas of Interest

1) Breast cancer,

2) Lung cancer

3) Gastrointestinal (colon, rectum, stomach, liver) cancers

4) Prostate cancer

5) Urogenital cancers

6) Head, neck cancers

7) Sarcoma treatments

8) Rare tumors

 

Research and publications.

Prognostic significance of high free T4 and low free T3 levels in non-thyroidal illness syndrome

…, D Kayaş, ET Canbaz, F Çetin, Ş Seçmeler… - European journal of …, 2018 - Elsevier

 

Background Non-thyroidal illness syndrome is characterized by decreased serum free T3 (FT3)

level and associates with long term mortality. Serum free T4 (FT4) may affect mortality …

 

Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: a retrospective study

…, S Ay, A Sakin, B Ertürk, Ş Selections… - European journal of …, 2021 - ncbi.nlm.nih.gov

 

Objective: This study aimed to determine the differences in clinicopathological features of

Turkish patients with high-risk breast cancer based on the mutation status of two breast cancer …

Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy

A Sakin, S Secmeler, S Arici, C Geredeli, N Yasar… - Scientific reports, 2019 - nature.com

 

Mean platelet volume (MPV), the most commonly used measure of platelet size, and is altered

in patients with malignancies. The aim of this study was to investigate the effect of MPV on …

 

The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer

…, C Geredeli, R Cekin, Ş Selections… - Journal of Oncology …, 2020 - journals.sagepub.com

 

Introduction To evaluate the predictive significance of pretreatment metabolic tumor volume

on pathologic response in patients who received neoadjuvant chemotherapy for breast …

 

Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer

A Topcu, MM Atci, S Secmeler, M Besiroglu… - Future …, 2021 - Future Medicine

 

Aim: To evaluate the efficacy of trastuzumab and potential risk factors on survival in patients

with HER2-positive metastatic gastric cancer. Methods: We retrospectively included 138 …

The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy

S Arici, C Geredeli, S Secmeler, R Cekin… - Current Problems in …, 2020 - Elsevier

Purpose To determine the effects of diabetes and fasting plasma glucose (FPG) level on the

pathologic response in patients with breast cancer who received neoadjuvant chemotherapy…

Major and minor salivary gland cancers: A multicenter retrospective study

…, NS Demirci, E Turkmen, T Şakalar, S Secmeler… - Head & …, 2023 - Wiley Online Library

Background Most of the studies on salivary gland cancers are limited for various reasons

such as being single‐center, small number of patients, including only major or minor SGCs, or …

Prognostic significance of primary tumor localization in stage II and III colon cancer

A Sakin, S Arici, S Secmeler, O Can… - World Journal of …, 2018 - ncbi.nlm.nih.gov

AIM To investigate the effects of tumor localization on disease free survival (DFS) and overall

survival (OS) in patients with stage II-III colon cancer. METHODS This retrospective study …

Factors affecting survival in neuroendocrine tumors: a 15-year single center experience

A Sakin, M Tambas, S Secmeler, O Can… - Asian Pacific Journal …, 2018 - ncbi.nlm.nih.gov

Background: Neuroendocrine tumors are a heterogeneous group of tumors that can originate

from all of the neuroendocrine cells in the body, mostly from the gastrointestinal tract. In…

The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer

A Sakin, NS Samanci, S Secmeler, S Arici… - Journal of cancer …, 2020 - journals.lww.com

Materials and Methods: Patients that were followed up and treated in the Department of

Medical Oncology between 1999 and 2016 were retrospectively included in the study. patients…

 

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT

E Melekoglu, E Bayram, S Secmeler, B Mete, B Sahin - Nutrients, 2023 - mdpi.com

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

También le puede interesar

Pagos y Beneficios

Nuestros servicios no tienen costo

El pago se realiza directamente en la clínica o mediante transferencia a su cuenta bancaria oficial.

Reserva segura

Algunas clínicas pueden requerir un depósito como parte de su política.

Pagos en cuotas flexibles

Pague cómodamente en cuotas flexibles.

Programa de referencias

Reciba recompensas por recomendar Bookimed a sus amigos.